Login to Your Account

FDA Tells OGS That Vevesca Is Not Approvable For Gaucher's

By Nuala Moran

Wednesday, June 26, 2002
LONDON - Shares in Oxford GlycoSciences plc fell by 92.5 pence to £3 Monday after the company said the FDA had ruled its lead product, Vevesca, not approvable. At that price the market capitalization of OGS is less than its £170 million (US$255 million) cash pile. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription